Viking Therapeutics, Inc. (VKTX)

US — Healthcare Sector
Peers: MDGL  TGTX  TERN  HEPA  VSTM  AXSM 

Automate Your Wheel Strategy on VKTX

With Tiblio's Option Bot, you can configure your own wheel strategy including VKTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol VKTX
  • Rev/Share 0.0
  • Book/Share 7.0938
  • PB 3.7046
  • Debt/Equity 0.0011
  • CurrentRatio 25.8604
  • ROIC -0.2673

 

  • MktCap 2955053575.0
  • FreeCF/Share -1.3603
  • PFCF -19.373
  • PE -17.1783
  • Debt/Assets 0.0011
  • DivYield 0
  • ROE -0.1998

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation VKTX Cantor Fitzgerald -- Overweight -- $104 April 29, 2025
Initiation VKTX Goldman -- Neutral -- $30 April 8, 2025
Initiation VKTX Scotiabank -- Sector Outperform -- $102 Feb. 13, 2025
Initiation VKTX Citigroup -- Neutral -- $38 Feb. 7, 2025
Initiation VKTX JP Morgan -- Overweight -- $80 Sept. 11, 2024

News

Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
VKTX
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Neutral

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
VKTX
Published: September 25, 2025 by: Zacks Investment Research
Sentiment: Negative

VKTX faces rising pressure in the obesity drug race as Pfizer re-enters with a $4.9B Metsera deal and rivals scale up.

Read More
image for news Can Viking Therapeutics Hold Its Edge as Obesity Rivalry Heats Up?
Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
VKTX
Published: September 23, 2025 by: Seeking Alpha
Sentiment: Neutral

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Bernstein 2nd Annual Global Healthcare Conference September 23, 2025 11:20 AM EDT Company Participants Brian Lian - President, CEO & Director Conference Call Participants Courtney Breen - Sanford C. Bernstein & Co., LLC.

Read More
image for news Viking Therapeutics, Inc. (VKTX) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript
Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript
VKTX
Published: September 22, 2025 by: Seeking Alpha
Sentiment: Neutral

Viking Therapeutics, Inc. (NASDAQ:VKTX ) Q4 2023 Earnings Conference Call February 7, 2024 4:30 PM ET Company Participants Brian Lian - President and CEO Greg Zante - CFO Stephanie Diaz - Manager of IR Conference Call Participants Joon Lee - Truist Steven Seedhouse - Raymond James Jay Olson - Oppenheimer. Naz Rahman - Maxim Group.

Read More
image for news Viking Therapeutics, Inc. (VKTX) Q4 2023 Earnings Call Transcript
AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
AMGN, VKTX
Published: September 16, 2025 by: Zacks Investment Research
Sentiment: Positive

Amgen's MariTide and Viking's VK2735 show promise in obesity, but pipeline strength and performance set the two biotech players apart.

Read More
image for news AMGN vs. VKTX: Which Biotech Stock Is the Better Obesity Play?
Where Does VKTX Stock Stand After the Obesity Pill Setback?
VKTX
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Negative

Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.

Read More
image for news Where Does VKTX Stock Stand After the Obesity Pill Setback?
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
VKTX
Published: September 09, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
5 Stocks Poised to DOUBLE Your Money by 2027
ACHR, JOBY, QBTS, RGTI, SOUN, VKTX, ZENA
Published: September 09, 2025 by: 24/7 Wall Street
Sentiment: Positive

Read More
image for news 5 Stocks Poised to DOUBLE Your Money by 2027
Viking Therapeutics Loses 20% in a Month: How to Play the Stock
VKTX
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Negative

VKTX stock slumps after mixed obesity pill study results raise safety concerns and highlight fierce market competition.

Read More
image for news Viking Therapeutics Loses 20% in a Month: How to Play the Stock
Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
NVO, VKTX
Published: August 27, 2025 by: Zacks Investment Research
Sentiment: Positive

NVO and VKTX face setbacks and rising competition as they battle for ground in the GLP-1 obesity market.

Read More
image for news Novo Nordisk vs. Viking Therapeutics: Which GLP-1 Stock is a Safer Bet?
Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
VKTX
Published: August 21, 2025 by: Zacks Investment Research
Sentiment: Negative

Viking Therapeutics stock sinks after mixed results from its obesity pill trial, raising doubts over safety, tolerability and future prospects.

Read More
image for news Post Obesity Pill Results Reveal: Buy, Sell or Hold VKTX Stock?
Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
VKTX
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Negative

VKTX shares plunge after mixed obesity pill study data shows weight loss success but high dropout rates.

Read More
image for news Viking Therapeutics' Stock Tanks on Mixed Data From Obesity Pill Study
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
VKTX
Published: August 20, 2025 by: Zacks Investment Research
Sentiment: Positive

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Read More
image for news Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
Viking Therapeutics: What's Happening With VKTX Stock?
VKTX
Published: August 20, 2025 by: Forbes
Sentiment: Negative

Viking Therapeutics (NASDAQ: VKTX) fell 42% on August 19, 2025, after Phase 2 results for its oral obesity pill VK2735 disappointed investors. The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli Lilly and Novo Nordisk.

Read More
image for news Viking Therapeutics: What's Happening With VKTX Stock?
The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin
VKTX
Published: August 19, 2025 by: CNBC Television
Sentiment: Positive

Justin Zelin, BTIG senior biotech analyst, joins 'The Exchange' to discuss GLP-1's and the share decline for Viking Therapeutics and why he's still bullish the stock.

Read More
image for news The market reaction is overdone on Viking Therapeutics, says BTIG's Justin Zelin
Viking Therapeutics plummets on new obesity drug data. Here's a breakdown
VKTX
Published: August 19, 2025 by: CNBC Television
Sentiment: Negative

CNBC's Angelica Peebles joins 'Money Movers' to discuss Viking Therapy shares plummeting on new obesity drug data.

Read More
image for news Viking Therapeutics plummets on new obesity drug data. Here's a breakdown
Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
VKTX
Published: August 19, 2025 by: Investopedia
Sentiment: Negative

Viking Therapeutics (VKTX) shares cratered nearly 45% Tuesday when the biopharma firm reported study of its experimental weight-loss pill raised concerns about side effects.

Read More
image for news Viking Therapeutics Stock Plunges on Oral Weight-Loss Pill Study Results
Viking Therapeutics shares plunge on weight loss trial tolerability concerns
VKTX
Published: August 19, 2025 by: Proactive Investors
Sentiment: Negative

Viking Therapeutics (NASDAQ:VKTX) shares tumbled 43% on Tuesday following the release of data from its Phase 2a Venture Oral weight loss trial showing strong efficacy but raised tolerability concerns. The study showed that participants taking VK-2735 achieved placebo-adjusted weight losses of approximately 7.5% at 60 mg, 10% at 90 mg, and 11% at 120 mg over 13 weeks.

Read More
image for news Viking Therapeutics shares plunge on weight loss trial tolerability concerns
Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success
VKTX
Published: August 19, 2025 by: Seeking Alpha
Sentiment: Negative

Viking Therapeutics, Inc.'s VK2735 oral trial met efficacy and safety endpoints, but high discontinuation rates and modest weight loss disappointed Wall Street, triggering a steep sell-off. Despite being underwhelming compared to Novo and Lilly's oral GLP-1 drugs, VK2735 remains a top-three candidate in a massive, rapidly growing obesity market. Phase 3 injectable VK2735 data will be more decisive, and the market's expectations for weight loss drugs may need to be reset to more realistic levels.

Read More
image for news Viking Therapeutics: Wall Street Mistaken To Dump After Obesity Pill Study Success
Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data
VKTX
Published: August 19, 2025 by: Forbes
Sentiment: Negative

The once-daily pill VK2735 had lower weight-loss results on average compared to Eli Lilly's orforglipron, which was tested over 72 weeks. The highest dose of Eli Lilly's once-daily treatment helped patients lose about 12.4% of their body weight in a late-stage trial, well below analyst expectations of 15%, according to FactSet.

Read More
image for news Viking Therapeutics Shares Nosedive Toward Worst Day Ever After Obesity Trial Data
Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
VKTX
Published: August 19, 2025 by: CNBC
Sentiment: Negative

Shares of Viking Therapeutics fell more than 30% on Tuesday after the company released mid-stage trial data on its obesity pill that disappointed investors. While the weight loss caused by Viking's pill was roughly comparable to that of other oral drugs, the side effects and discontinuation rates appeared to rattle Wall Street.

Read More
image for news Viking Therapeutics shares fall more than 30% on disappointing obesity pill trial data
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
LLY, VKTX
Published: August 19, 2025 by: Benzinga
Sentiment: Negative

On Tuesday, Viking Therapeutics Inc. VKTX released the much-awaited data from its Phase 2 trial of VK2735 pill, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors.

Read More
image for news Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks
Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
VKTX
Published: August 19, 2025 by: Market Watch
Sentiment: Negative

Viking Therapeutics on Tuesday announced that a trial showed its oral weight-loss drug works — and like a larger rival, its stock price immediately suffered.

Read More
image for news Viking Therapeutics' stock tumbles after results of oral weight-loss drug trial. It has company.
Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
VKTX
Published: August 04, 2025 by: Zacks Investment Research
Sentiment: Positive

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Read More
image for news Viking Therapeutics (VKTX) Is Considered a Good Investment by Brokers: Is That True?
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
VKTX
Published: July 24, 2025 by: Zacks Investment Research
Sentiment: Negative

Shares of Viking slide after Q2 loss widens to 58 cents per share on rising R&D and nil revenues, missing estimates by 14 cents.

Read More
image for news VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
VKTX
Published: July 21, 2025 by: Zacks Investment Research
Sentiment: Positive

With no revenue expected, VKTX's Q2 report is likely to have the spotlight on pipeline moves across its obesity drugs.

Read More
image for news Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
VKTX
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Neutral

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Read More
image for news Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
VKTX
Published: July 10, 2025 by: Seeking Alpha
Sentiment: Neutral

Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies

Read More
image for news Viking Therapeutics: What's Next After GLP-1 Hype Dies Down And Competition Intensifies
Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
VKTX
Published: July 03, 2025 by: Zacks Investment Research
Sentiment: Neutral

Viking Therapeutics, Inc. (VKTX) closed at $28.19 in the latest trading session, marking a +1.7% move from the prior day.

Read More
image for news Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts
Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts
VKTX
Published: July 03, 2025 by: Seeking Alpha
Sentiment: Positive

VK2735 shows strong early weight-loss data, positioning Viking as a potential third major player in the booming GLP-1 obesity drug market. Despite a sharp stock decline, Viking is well-funded, with $850M cash and large pivotal trials underway for both injectable and oral VK2735. Viking doesn't need to outperform Lilly or Novo; meeting FDA approval thresholds could secure blockbuster status in a massive, multi-drug market.

Read More
image for news Viking: I'm Bullish On Oral/Injectable GLP-1 Obesity Data Catalysts

About Viking Therapeutics, Inc. (VKTX)

  • IPO Date 2015-04-28
  • Website https://www.vikingtherapeutics.com
  • Industry Biotechnology
  • CEO Brian Lian
  • Employees 45

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.